1330180-51-2
1330180-51-2
Chemical Structure
Ramifenazone-d7
- CAS No.: 1330180-51-2
- Formula:C14H12D7N3O
- Molecular Weight:252.36
IUPAC Name: 1,5-dimethyl-2-phenyl-4-((propan-2-yl-d7)amino)-1,2-dihydro-3H-pyrazol-3-one
InChIKey: XOZLRRYPUKAKMU-SVMCCORHSA-N
SMILES: O=C1N(N(C)C(C)=C1NC(C([2H])([2H])[2H])(C([2H])([2H])[2H])[2H])C2=CC=CC=C2
Biological Activity: Ramifenazone-d7 is the deuterium labeled Ramifenazone. Ramifenazone (Isopropylaminoantipyrine) is a pyrazole derivative and acts as a non-steroidal anti-inflammatory agent (NSAID). Ramifenazone has analgesic, antipyretic, anti-inflammatory and antimicrobial activities[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ramifenazone-d7 | Ramifenazone-d7 is the deuterium labeled Ramifenazone. Ramifenazone (Isopropylaminoantipyrine) is a pyrazole derivative and acts as a non-steroidal anti-inflammatory agent (NSAID). Ramifenazone has analgesic, antipyretic, anti-inflammatory and antimicrobial activities. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ramifenazone (Standard) | ≥98% | Ramifenazone (Standard) is the analytical standard of Ramifenazone. This product is intended for research and analytical applications. Ramifenazone (Isopropylaminoantipyrine) is a pyrazole derivative and acts as a non-steroidal anti-inflammatory agent (NSAID). Ramifenazone has analgesic, antipyretic, anti-inflammatory and antimicrobial activities. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ramifenazone | 98.99% | Ramifenazone (Isopropylaminoantipyrine) is a pyrazole derivative and acts as a non-steroidal anti-inflammatory agent (NSAID). Ramifenazone has analgesic, antipyretic, anti-inflammatory and antimicrobial activities. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Bhupender Nehra, et al. Recent advancements in the development of bioactive pyrazoline derivatives. Eur J Med Chem. 2020 Nov 1;205:112666. [Content Brief]
